IDiyas

For the Inventor, By the Inventor

Medfield, MA, United States of America

Matthew Lloyd Childers

USPTO Granted Patents = 19 

 

 

Average Co-Inventor Count = 12.3

ph-index = 4

Forward Citations = 39(Granted Patents)


Location History:

  • Newton Highlands, MA (US) (2013)
  • Boston, MA (US) (2019)
  • Medfield, MA (US) (2016 - 2023)

Company Filing History:

goldMedal19 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents

Years Active: 2013-2025

where 'Filed Patents' based on already Granted Patents

19 patents (USPTO):
1. 12240867 - Arginase inhibitors and methods of use (2025-03-04),
2. 12215116 - Arginase inhibitors and methods of use (2025-02-04),
3. 11685761 - Cyclic di-nucleotide compounds as sting agonists (2023-06-27),
4. 11311528 - Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors (2022-04-26),
5. 10793557 - Sting agonist compounds (2020-10-06),
6. 10766919 - Cyclic di-nucleotide compounds as sting agonists (2020-09-08),
7. 10759825 - Cyclic di-nucleotide compounds as STING agonists (2020-09-01),
8. 10738074 - Cyclic di-nucleotide compounds as STING agonists (2020-08-11),
9. 10508108 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-12-17),
10. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),
11. 10155765 - Carboxamide inhibitors of IRAK4 activity (2018-12-18),
12. 10086000 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2018-10-02),
13. 9969749 - Inhibitors of IRAK4 activity (2018-05-15),
14. 9957264 - Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors (2018-05-01),
15. 9932350 - Inhibitors of IRAK4 activity (2018-04-03),

Title: Matthew Lloyd Childers: A Pioneer in Arginase Inhibitors

Introduction: Matthew Lloyd Childers, located in Medfield, MA, is an accomplished inventor with a significant portfolio of 19 patents. His work primarily focuses on developing innovative compounds that target arginase-related diseases. Matthew's contributions to the field of medicinal chemistry are noteworthy, and his latest inventions showcase his dedication to improving healthcare.

Latest Patents: Among Matthew's latest patents are innovative compounds formulated as arginase inhibitors. These compounds, represented as Formula (I) in his patents, serve as vital therapeutic agents. They hold the promise of preventing and treating various diseases associated with arginase, demonstrating significant potential in the pharmaceutical industry.

Career Highlights: Matthew has built a remarkable career at Merck Sharp & Dohme Corporation, where he has applied his expertise in medicinal chemistry and pharmacology. His innovative approaches have led to advancements in the development of arginase inhibitors, solidifying his reputation as a leading inventor in his field.

Collaborations: Throughout his career, Matthew has collaborated with talented colleagues including Michael D. Altman and Jongwon Lim. These partnerships have enhanced his research and development initiatives, fostering an environment of creativity and innovation within the pharmaceutical sector.

Conclusion: Matthew Lloyd Childers exemplifies the spirit of innovation in the pharmaceutical industry. With his 19 patents and focus on arginase inhibitors, he continues to make significant strides towards understanding and treating arginase-related diseases. His dedication and collaboration with esteemed colleagues further underscore the importance of teamwork in driving technological advances in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…